Arbaclofen placarbil information

Arbaclofen placarbil
Clinical data
Pregnancy; category	N/A;
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name (3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid;
CAS Number	847353-30-4;
PubChem CID	11281011;
ChemSpider	9456008;
UNII	W89H91R7VX;
KEGG	D08861 ;
ChEMBL	ChEMBL2107312 ;
CompTox Dashboard (EPA)	DTXSID40233754 ;
ECHA InfoCard	100.221.150
Chemical and physical data
Formula	C19H26ClNO6
Molar mass	399.87 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C;
	InChI InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1; Key:JXTAALBWJQJLGN-KSSFIOAISA-N;

Arbaclofen placarbil (/ɑːrˈbækloʊfɛn pləˈkɑːrbɪl/ ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.^[1]

It is being developed as an addiction medicine to treat alcoholism. ^[2] It is also studied as a potential therapeutic for some autistic subjects.^[3]

^ "XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients". XenoPort, Inc. May 20, 2013. Archived from the original on 2013-12-02. Retrieved 2013-06-03.
^ Anderson E (3 July 2020). "Pill that replaces alcohol aims to end 'glass of wine' craving". The i newspaper. Associated Newspapers Limited.
^ Huang Q, Pereira AC, Velthuis H, Wong NM, Ellis CL, Ponteduro FM, et al. (January 2022). "GABA_B receptor modulation of visual sensory processing in adults with and without autism spectrum disorder" (PDF). Science Translational Medicine. 14 (626): eabg7859. doi:10.1126/scitranslmed.abg7859. PMID 34985973. S2CID 245771626.

[Results-1] "XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients". XenoPort, Inc. May 20, 2013. Archived from the original on 2013-12-02. Retrieved 2013-06-03.

[2] Anderson E (3 July 2020). "Pill that replaces alcohol aims to end 'glass of wine' craving". The i newspaper. Associated Newspapers Limited.

[3] Huang Q, Pereira AC, Velthuis H, Wong NM, Ellis CL, Ponteduro FM, et al. (January 2022). "GABA_B receptor modulation of visual sensory processing in adults with and without autism spectrum disorder" (PDF). Science Translational Medicine. 14 (626): eabg7859. doi:10.1126/scitranslmed.abg7859. PMID 34985973. S2CID 245771626.

Arbaclofen placarbil information

and 26 Related for: Arbaclofen placarbil information

Arbaclofen placarbil

Baclofen

Phenibut

Calcium channel blocker

GABA analogue

Glutamine

Tolperisone

GABA receptor agonist

Pentylenetetrazol

Fipronil

Flecainide

Oxcarbazepine

Diltiazem

Amlodipine

Kava

Thiazide

Lemon balm

Meclizine

Penicillin

Ranolazine

Glipizide

Picamilon

Procaine

Gliclazide

Benzocaine

Zonisamide

Clinical data

Pregnancy category	N/A
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name (3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid
CAS Number	847353-30-4
PubChem CID	11281011
ChemSpider	9456008
UNII	W89H91R7VX
KEGG	D08861^Y
ChEMBL	ChEMBL2107312^Y
CompTox Dashboard (EPA)	DTXSID40233754
ECHA InfoCard	100.221.150
Chemical and physical data
Formula	C₁₉H₂₆ClNO₆
Molar mass	399.87 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C
InChI InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1 Key:JXTAALBWJQJLGN-KSSFIOAISA-N